Amylyx Pharmaceuticals, Inc.
General ticker "AMLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Amylyx Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 34.4%.
Estimated limits based on current volatility of 5.4%: low 33.04$, high 35.57$
Factors to consider:
- Total employees count: 136 (+10.6%) as of 2025
- Top business risk factors: Operational and conduct risks, Significant losses, Financing unavailable, Clinical trial failure, Regulatory and compliance
- Current price 108.2% above estimated high
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.33$, 16.57$]
- 2026-12-31 to 2027-12-31 estimated range: [4.12$, 11.53$]
Financial Metrics affecting the AMLX estimates:
- Negative: with PPE of -7.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.63 <= 0.28
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 91.77 > 63.63
- Positive: Investing cash flow per share per price, % of 1.21 > -0.64
- Negative: negative Industry operating cash flow (median)
Short-term AMLX quotes
Long-term AMLX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $380.79MM | $87.37MM | $0.00MM |
| Operating Expenses | $341.98MM | $402.10MM | $153.29MM |
| Operating Income | $38.80MM | $-314.73MM | $-153.29MM |
| Non-Operating Income | $15.49MM | $12.60MM | $8.60MM |
| R&D Expense | $128.19MM | $140.29MM | $90.40MM |
| Income(Loss) | $54.30MM | $-302.14MM | $-144.69MM |
| Taxes | $5.03MM | $-0.39MM | $0.05MM |
| Net Income(Loss)* | $49.27MM | $-301.74MM | $-144.74MM |
| Stockholders Equity | $433.43MM | $164.76MM | $305.26MM |
| Inventory | $38.32MM | $0.00MM | $0.00MM |
| Assets | $517.45MM | $193.63MM | $332.64MM |
| Operating Cash Flow | $11.92MM | $-167.65MM | $-123.34MM |
| Capital expenditure | $1.24MM | $0.16MM | $0.14MM |
| Investing Cash Flow | $92.05MM | $75.65MM | $14.04MM |
| Financing Cash Flow | $3.54MM | $0.35MM | $257.03MM |
| Earnings Per Share** | $0.73 | $-4.43 | $-1.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.